Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional-dose vs low-dose platinum-gemcitabine plus delayed sintilimab for first-line advanced squamous non-small cell lung cancer
ChiCTR2200060803Phase 4Not yet recruiting
- Sponsor
- Quzhou People's Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sintilimab, gemcitabine, cisplatin and carboplatin in Pulmonary squamous cell carcinoma (2 arms), sponsored by Quzhou People's Hospital. Primary endpoints: Objective response rate, Progression-free survival and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
sintilimabgemcitabinecisplatincarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2200060803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060803.